Recently, NHU has secured approval for domestic drug registration of its API Coenzyme Q10, positioning the company as the first enterprise to receive such approval since the issuance of the National Medical Products Administration (NMPA)'s Announcement on Matters Related to Further Improving the Review, Approval, and Supervision of Drugs in 2019. This significant milestone indicates that our Coenzyme Q10 is at the forefront of the industry and paves the way for a new API market, presenting fresh opportunities for our development.

About Coenzyme Q10

Coenzyme Q10, a fat-soluble antioxidant, plays a crucial role in fortifying the myocardium, preventing heart aging, preventing and combating cancer, maintaining cardiovascular health, and enhancing overall vitality. The significant market demand for Coenzyme Q10 exists both domestically and internationally. The production of API Coenzyme Q10 necessitates stringent quality control and safety inspections, leading to rigorous requirements for production processes and product quality. NHU stands out as the inaugural company to receive such approval and recognition, demonstrating the company’s capability to produce high-quality API Coenzyme Q10 since the drug approval reform by the NMPA in 2019.

In its role as a guardian of nutrition and health, NHU is committed to the journey of open innovation. Starting from addressing future and potential market needs, we collaborate with academia and industry to delve into the cutting edges of chemical and biological science and technology and foster innovation and advancement, leading to the successful development of products like the Vitamin Series, Moxifloxacin Hydrochloride, and Taurine. NHU aims to create value for the entire industry and society, establishing a "Safety Moat" for human health.